L Meijer Selected Research

indirubin-3'-monoxime

6/2001	Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest.
1/2001	Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
1/2001	Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

L Meijer Research Topics

Disease

6	Neoplasms (Cancer) 12/2014 - 04/2000
5	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2000
2	Neuroblastoma 12/2014 - 10/2008
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2006 - 06/2001
2	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2000 - 01/2000
1	Neurobehavioral Manifestations 01/2022
1	Cystic Fibrosis (Mucoviscidosis) 11/2014
1	Cryptorchidism (Undescended Testes) 03/2012
1	Testicular Neoplasms (Testicular Cancer) 03/2012
1	Hypospadias 03/2012
1	Breast Neoplasms (Breast Cancer) 07/2010
1	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 10/2008
1	Chronic Kidney Failure (Chronic Renal Failure) 03/2008
1	Kidney Diseases (Kidney Disease) 03/2008
1	Infections 12/2001
1	Acquired Immunodeficiency Syndrome (AIDS) 08/2001
1	Necrosis 06/2001
1	Aneuploidy (Aneuploid) 06/2001
1	Polyploidy 06/2001
1	Malaria 05/2001
1	Endotoxin Hyporesponsiveness 04/2001
1	Alopecia (Baldness) 04/2001
1	Leukemia 01/2001
1	Chronic Disease (Chronic Diseases) 01/2001
1	Carcinoma (Carcinomatosis) 01/2001
1	Parkinson Disease (Parkinson's Disease) 01/2000
1	Pheochromocytoma 01/2000

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2000
4	indirubinIBA 10/2006 - 04/2000
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 12/2014 - 06/2000
3	Phosphotransferases (Kinase)IBA 12/2014 - 01/2000
3	indirubin-3'-monoximeIBA 06/2001 - 01/2001
3	Carrier Proteins (Binding Protein)IBA 01/2001 - 01/2000
2	RoscovitineIBA 12/2014 - 10/2008
2	Pharmaceutical PreparationsIBA 03/2008 - 04/2000
2	indoleIBA 06/2001 - 01/2001
2	Protein Kinases (Protein Kinase)IBA 05/2001 - 01/2001
2	Glycogen Synthase Kinase 3IBA 01/2001 - 01/2000
1	Protein Kinase InhibitorsIBA 01/2022
1	((5Z)5- (1,3- benzodioxol- 5- yl)methylene- 2- phenylamino- 3,5- dihydro- 4H- imidazol- 4- one)IBA 01/2022
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 11/2014
1	Caspase 3 (Caspase-3)IBA 01/2014
1	InterferonsIBA 01/2014
1	Endocrine DisruptorsIBA 03/2012
1	Small Interfering RNA (siRNA)IBA 07/2010
1	Cyclin EIBA 07/2010
1	Trastuzumab (Herceptin)FDA Link 07/2010
1	purineIBA 10/2008
1	CarbazolesIBA 03/2005
1	Antiparasitic Agents (Antiparasitics)IBA 12/2001
1	Antimitotic AgentsIBA 12/2001
1	pancratistatinIBA 12/2001
1	7-deoxynarciclasineIBA 12/2001
1	Antiviral Agents (Antivirals)IBA 08/2001
1	NIMA-Related KinasesIBA 05/2001
1	Toll-Like Receptor 4IBA 04/2001
1	CyclinsIBA 04/2001
1	Glycogen Synthase (Synthase I)IBA 01/2001
1	ElementsIBA 12/2000
1	LipidsIBA 12/2000
1	Cyclin D1IBA 12/2000
1	GlycogenIBA 12/2000
1	beta CateninIBA 12/2000
1	Insulin (Novolin)FDA Link 12/2000
1	alsterpaulloneIBA 10/2000
1	EnzymesIBA 10/2000
1	Glycogen Synthase Kinase 3 betaIBA 10/2000
1	StaurosporineIBA 04/2000
1	alvocidib (flavopiridol)IBA 04/2000
1	alpha-SynucleinIBA 01/2000
1	hymenialdisineIBA 01/2000
1	Biological ProductsIBA 01/2000
1	AntibodiesIBA 01/2000

Therapy/Procedure

2	Chinese Traditional Medicine (Traditional Chinese Medicine) 06/2001 - 01/2001
1	Drug Therapy (Chemotherapy) 04/2001
1	Therapeutics 04/2001